Joint Suit. If ULRF and Licensee so agree, they may institute suit jointly. If so, they will: (a) prosecute the suit in both their names; (b) bear the out-of-pocket costs equally; (c) share any recovery or settlement equally; and (d) agree in a separate written document how they will exercise control over the action. In the event that a non-cash cross license is awarded or a non-cash settlement is reached, both Parties agree to negotiate appropriate compensation in good faith
Appears in 3 contracts
Sources: Exclusive License Agreement (Neuro Spectrum Insights, Inc.), Exclusive License Agreement (Neuro Spectrum Insights, Inc.), Exclusive License Agreement (Ritter Pharmaceuticals Inc)
Joint Suit. If ULRF and Licensee so agreeagree (or if Licensee so elects pursuant to Section 11.2), they may institute suit jointly. If so, they will: (a) prosecute the suit in both their names; (b) bear the out-of-pocket costs equally; (c) share any recovery or settlement equally; and (d) agree in a separate written document how they will exercise control over the action. In the event that a non-cash cross license is awarded or a non-cash settlement is reached, both Parties agree to negotiate appropriate compensation in good faith
Appears in 2 contracts
Sources: Exclusive License Agreement (Qualigen Therapeutics, Inc.), Exclusive License Agreement (Qualigen Therapeutics, Inc.)
Joint Suit. If ULRF and Licensee so agree, they may institute suit jointly. If so, they will: (a) prosecute the suit in both their names; (b) bear the out-of-pocket costs equally; (c) share any recovery or settlement equally; and (d) agree in a separate written document how they will exercise control over the action. In the event that a non-cash cross license is awarded or a non-cash settlement is reached, both Parties agree to negotiate appropriate compensation in good faith.
Appears in 2 contracts
Sources: Exclusive License Agreement (Talaris Therapeutics, Inc.), Exclusive License Agreement (Talaris Therapeutics, Inc.)